AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs AdvisorSAN DIEGO, CA - January 20, 2026 ( NEWMEDIAWIRE ) - AXIM Biotechnologies, Inc. (“AXIM” or the “Company”) (OTC:AXIM), a diagnostic and biotechnology company advancing clinically validated solutions for ocular and inflammatory diseases, today announced the engagement of 624 Advisors, which is owned and managed by Alan J. Touch, OD, as Chief Medical & Regulatory Affairs Advisor. Dr. Touch is considered a preeminent IVD and CDx SME and global regulatory specialist.
AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement With VisionPlus Corp. for TearScan(R) Lactoferrin and IgE Diagnostic Tests in South KoreaSAN DIEGO, CA - October 23, 2025 ( NEWMEDIAWIRE ) - AXIM Biotechnologies, Inc. (OTC:AXIM) (“AXIM”), a leader in rapid, point-of-care ocular diagnostics, today announced it has entered into an exclusive distribution agreement with VisionPlus Corp. (“VisionPlus”) to market and distribute AXIM’s TearScan® Lactoferrin Test for the detection of aqueous-deficient dry eye (ADDE) and TearScan® IgE Test for ocular allergy throughout South Korea.
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s
AXIM Biotechnologies Announces Exclusive Latin America License & Distribution Agreement With JK Medical for TearScan(R) Ocular Diagnostic TestsSAN DIEGO, CA - October 7, 2025 ( NEWMEDIAWIRE ) - AXIM Biotechnologies, Inc. (OTC: AXIM), a diagnostics company focused on rapid, point-of-care ophthalmic testing, today announced it has entered into an exclusive license and distribution agreement with JK Medical, Inc. (“JK Medical”) initially covering seven Latin American countries: Brazil, Chile, Peru, Argentina, Mexico, Ecuador, and Colombia. Under the agreement, JK Medical will market and distribute AXIM’s TearScan® Lactoferrin Diagnostic Test for aiding in the diagnosis of aqueous-deficient Dry Eye Disease (DED) and the TearScan® IgE Diagnostic Test for aiding in the diagnosis of allergic conjunctivitis within the covered territory.
Axim Biotechnologies Files Pre-Submission With FDA for CLIA Waiver Pathway on Lactoferrin Point-of-Care Diagnostic TestSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
AXIM Biotechnologies Receives Medical Device Manufacturing LicenseSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
AXIM Biotechnologies Tear Based Testing Platform Continues to Gain Traction After Successful Clinical ValidationSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
AXIM Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay ProductionLeading Diagnostic Healthcare Company Signs Contract Manufacturing Agreement in Order to Fulfill Sales of IgE and Lactoferrin DED Diagnostic Assays
AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease
AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has successfully developed the world’s first rapid, point-of-care, non-invasive diagnostic assay for the detection of abnormal alpha-synuclein, a known biomarker for Parkinson’s Disease (PD).
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today the receipt of notification by the United States Patent & Trademark Office of several patent allowances.
Update: AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers NationwideSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers NationwideSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform LaunchSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
AXIM Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing UnitSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
AXIM Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular Diagnostic AssaysSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
AXIM Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay ManufacturingSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Medical Marijuana, Inc. Appoints New CEO; Highlights Renewed Focus on Profitability, Further ExpansionSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
AXIM Biotechnologies Files Patent on Fentanyl Neutralizing Antibody Test, Applies for DEA License to Work With Controlled SubstanceSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional PatentLeading Diagnostic Healthcare Company Announces Development of and Provisional Patent Filing on First-of-Its-Kind Point-of-Care Ophthalmological Diagnostic Solution Enabling Precision Treatment of Common Eye Conditions
AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic SolutionsTechnology and Benefits Company At Forefront of Leading Ophthalmological Media Outlets’ Coverage of Innovative Diagnostic Solutions
